William Volz - LogicBio Therapeutics President
LOGCDelisted Stock | USD 2.07 0.00 0.00% |
President
Mr. William J. Volz is President Chief Executive Officer Director of Logic Devices Inc. He has served as a director since he cofounded Company in 1983. He has served as President and Chief Executive Officer since December 1987. Mr. Volz served as Vice President of Engineering from August 1983 to December 1987. With over 43 years of experience in the semiconductor industry and with ou Company. since 1987.
Age | 63 |
Tenure | 37 years |
Phone | 617 245-0399 |
Web | www.logicbio.com |
LogicBio Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.3031) % which means that it has lost $0.3031 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.974) %, meaning that it created substantial loss on money invested by shareholders. LogicBio Therapeutics' management efficiency ratios could be used to measure how well LogicBio Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 5.01 M in liabilities with Debt to Equity (D/E) ratio of 0.54, which is about average as compared to similar companies. LogicBio Therapeutics has a current ratio of 2.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist LogicBio Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, LogicBio Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like LogicBio Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for LogicBio to invest in growth at high rates of return. When we think about LogicBio Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Sam Fischer | Diageo PLC ADR | 52 | |
Khushi Ram | Kulicke And Soffa | 47 | |
Alberto Gavazzi | Diageo PLC ADR | 50 | |
Hoang Hoang | Kulicke And Soffa | 57 | |
Kevin Doyle | Molson Coors Brewing | N/A | |
Samuel Fischer | Diageo PLC ADR | 51 | |
Peter Marino | Molson Coors Brewing | 51 | |
Debra Crew | Diageo PLC ADR | 54 | |
John Kennedy | Diageo PLC ADR | 59 | |
YihNeng Lee | Kulicke And Soffa | 56 | |
Nelson Wong | Kulicke And Soffa | 57 | |
Chan Chong | Kulicke And Soffa | 55 | |
Ewan Andrew | Diageo PLC ADR | N/A | |
Ichiro Aoki | Indie Semiconductor | 58 | |
Joyce Lim | Kulicke And Soffa | 55 | |
Deirdre Mahlan | Diageo PLC ADR | 56 | |
John OKeeffe | Diageo PLC ADR | 52 | |
Nicholas Blazquez | Diageo PLC ADR | 52 | |
Dayalan Nayager | Diageo PLC ADR | 43 | |
Richard Simoncic | Microchip Technology | 60 | |
David Cutter | Diageo PLC ADR | 48 |
Management Performance
Return On Equity | -0.97 | |||
Return On Asset | -0.3 |
LogicBio Therapeutics Leadership Team
Elected by the shareholders, the LogicBio Therapeutics' board of directors comprises two types of representatives: LogicBio Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of LogicBio. The board's role is to monitor LogicBio Therapeutics' management team and ensure that shareholders' interests are well served. LogicBio Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, LogicBio Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Robert Stanley, Independent Director | ||
Daniel MD, Chief Officer | ||
Matthias Jaffe, CFO | ||
Michael Wyzga, Director | ||
Mariana Nacht, Chief Officer | ||
Leszek MBA, CoFounder Board | ||
William Volz, Founder, Chief Executive Office and President and Director | ||
Frederic MBA, CEO Pres | ||
James Hooper, Director | ||
Hal Shoemaker, Independent Director | ||
Kimiko Milheim, Chief Financial officer, Principal Accounting officer and Secretary | ||
Frederic Chereau, President CEO, Director | ||
Andrea JD, Gen Sec | ||
Adi Barzel, CoFounder | ||
Howard Farkas, Independent Chairman of the Board | ||
Dean Falb, Chief Scientific Officer | ||
Matthias Hebben, Global Devel | ||
Tom Wilton, Chief Business Officer | ||
Grace Lochhead, VP HR | ||
Joshua Blacher, Principal CFO | ||
Sandra Poole, COO | ||
Richard Moscicki, Director |
LogicBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is LogicBio Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.97 | |||
Return On Asset | -0.3 | |||
Profit Margin | (2.47) % | |||
Operating Margin | (2.41) % | |||
Current Valuation | 40.47 M | |||
Shares Outstanding | 32.96 M | |||
Shares Owned By Insiders | 8.93 % | |||
Shares Owned By Institutions | 48.70 % | |||
Number Of Shares Shorted | 274.42 K | |||
Price To Earning | (3.53) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards LogicBio Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, LogicBio Therapeutics' short interest history, or implied volatility extrapolated from LogicBio Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the LogicBio Therapeutics information on this page should be used as a complementary analysis to other LogicBio Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Other Consideration for investing in LogicBio Stock
If you are still planning to invest in LogicBio Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LogicBio Therapeutics' history and understand the potential risks before investing.
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |